Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial

By sjmartinez • August 31, 2023

Moser CB, Chew KW, Ritz J, Newell M, Javan AC, Eron JJ, Daar ES, Wohl DA, Currier JS, Smith DM, Hughes MD; ACTIV-2/A5401 Study Team. Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial. J Infect Dis. 2023 Aug 31;228(Supplement_2):S92-S100. doi: 10.1093/infdis/jiad209. PMID: 37650234.

Tags: adaptive platform trials, covid-19, Harbor UCLA, Infectious Diseases, pooled placebo, Publications, randomization

Spinal Implant-Associated Infection in Type 2 and Type 1 Diabetes: Phenotype-Specific Inflammatory Features and Therapeutic Response to Semaglutide

Olson TE, Lloyd TS, Hamad CD, Chun RF, Wiener J, Golzar A, Mehany J, Shahamatdar S, Kittredge A, Pearce L, Francis KP, Obeidin F, Holly[...]

How We Plan Preconception in Systemic Lupus Erythematosus and Manage Lupus Nephritis in Pregnancy

Dukkipati R, Shah A, Desai S. How We Plan Preconception in Systemic Lupus Erythematosus and Manage Lupus Nephritis in Pregnancy. Clin J Am Soc Nephrol.[...]

Effect of Omega-3 fatty acids, fibrates and PCSK9 inhibitors on atherosclerotic plaque burden, composition and stability: Insights from imaging

Roman S, Budoff MJ. Effect of Omega-3 fatty acids, fibrates and PCSK9 inhibitors on atherosclerotic plaque burden, composition and stability: Insights from imaging. Pharmacol Ther.[...]